Viking Therapeutics (NASDAQ: VKTX) and Novavax (NASDAQ: NVAX) were two of the big winners in the biotech industry last year.

Novavax reported $88 million in revenues in the fourth quarter, compared to $291 million the year prior, and $682 million for ...

Novavax NVAX is expected to report fourth-quarter and full-year 2024 earnings later this month. In the last reported quarter, ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...

In summary, our corporate growth strategy allows Novavax to focus on what we do best leveraging our scientific expertise and our proven technology platform to drive value through R&D and through ...

GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: ...

Novavax is also advancing core technology for different uses,like mucosal vaccination and high-density nanoparticles. Management intends to focus on exploring RSV-combination options and new ...